Literature DB >> 25676091

The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed.

Larissa Dirr1, Ibrahim M El-Deeb, Patrice Guillon, Cindy J Carroux, Leonard M G Chavas, Mark von Itzstein.   

Abstract

Human parainfluenza virus type 3 (hPIV-3) is one of the leading causes for lower respiratory tract disease in children, with neither an approved antiviral drug nor vaccine available to date. Understanding the catalytic mechanism of human parainfluenza virus haemagglutinin-neuraminidase (HN) protein is key to the design of specific inhibitors against this virus. Herein, we used (1) H NMR spectroscopy, X-ray crystallography, and virological assays to study the catalytic mechanism of the HN enzyme activity and have identified the conserved Tyr530 as a key amino acid involved in catalysis. A novel 2,3-difluorosialic acid derivative showed prolonged enzyme inhibition and was found to react and form a covalent bond with Tyr530. Furthermore, the novel derivative exhibited enhanced potency in virus blockade assays relative to its Neu2en analogue. These outcomes open the door for a new generation of potent inhibitors against hPIV-3 HN.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  haemagglutinin-neuraminidase; inhibitors; parainfluenza virus; sialic acid; sialidase mechanism

Mesh:

Substances:

Year:  2015        PMID: 25676091     DOI: 10.1002/anie.201412243

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  8 in total

1.  Influenza A Virus Neuraminidase Inhibitors.

Authors:  Nongluk Sriwilaijaroen; Christopher J Vavricka; Hiromasa Kiyota; Yasuo Suzuki
Journal:  Methods Mol Biol       Date:  2022

2.  Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase.

Authors:  Ibrahim M El-Deeb; Patrice Guillon; Larissa Dirr; Mark von Itzstein
Journal:  Medchemcomm       Date:  2016-10-05       Impact factor: 3.597

3.  Carboxybetaine Modified Interface for Electrochemical Glycoprofiling of Antibodies Isolated from Human Serum.

Authors:  Tomas Bertok; Alena Šedivá; Jaroslav Filip; Marketa Ilcikova; Peter Kasak; Dusan Velic; Eduard Jane; Martina Mravcová; Jozef Rovenský; Pavol Kunzo; Peter Lobotka; Vasilij Šmatko; Alica Vikartovská; Jan Tkac
Journal:  Langmuir       Date:  2015-06-17       Impact factor: 3.882

4.  A dual drug regimen synergistically blocks human parainfluenza virus infection.

Authors:  Benjamin Bailly; Larissa Dirr; Ibrahim M El-Deeb; Ralf Altmeyer; Patrice Guillon; Mark von Itzstein
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

5.  Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors.

Authors:  Tanguy Eveno; Larissa Dirr; Ibrahim M El-Deeb; Patrice Guillon; Mark von Itzstein
Journal:  Viruses       Date:  2019-05-05       Impact factor: 5.048

6.  Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.

Authors:  Jennifer L McKimm-Breschkin; Alicia M Fry
Journal:  Antiviral Res       Date:  2016-02-09       Impact factor: 5.970

7.  The acidic hydrolysis of N-acetylneuraminic 4,5-oxazoline allows a direct functionalization of the C5 position of Neu5Ac2en (DANA).

Authors:  Paola Rota; Paolo La Rocca; Federica Cirillo; Marco Piccoli; Pietro Allevi; Luigi Anastasia
Journal:  RSC Adv       Date:  2019-12-24       Impact factor: 3.361

8.  The impact of the butterfly effect on human parainfluenza virus haemagglutinin-neuraminidase inhibitor design.

Authors:  Larissa Dirr; Ibrahim M El-Deeb; Leonard M G Chavas; Patrice Guillon; Mark von Itzstein
Journal:  Sci Rep       Date:  2017-07-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.